"India business is going to grow, and continue to grow faster than our represented market, the initiatives we have taken in last few years and the Omicron coming up in the last quarter - some of the COVID related therapies like Azithromycin have seen sharp uptake in January," Pranav Amin, managing director, international business at Alembic Pharma told ET.from Stocks-Markets-Economic Times
Read The Rest:economictimes...
